Previous close | 177.02 |
Open | 179.86 |
Bid | 180.96 x 0 |
Ask | 181.12 x 0 |
Day's range | 179.86 - 179.86 |
52-week range | 126.80 - 189.54 |
Volume | |
Avg. volume | 29 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NEW YORK, June 14, 2024--JPMorgan Chase & Co. (NYSE: JPM) ("JPMorgan Chase" or the "Firm") has declared dividends on the outstanding shares of the Firm’s Series CC, FF and HH preferred stock. Information can be found on the Firm’s Investor Relations website at https://www.jpmorganchase.com/ir/news.
J.P. Morgan Private Capital, a venture capital and growth equity investment team within J.P. Morgan Asset Management, today announced the final close of the first Life Sciences Private Capital offering, 270 Life Sciences Private Capital Fund I (the "Fund"), led by Chief Investment Officer Stephen Squinto, Ph.D. and Managing Partner Gaurav Gupta, M.D., M.S.E. The fund closed above its $500 million target, attracting strong support from investors, including institutional allocators, strategic corp
NEW YORK, June 11, 2024--As previously announced, JPMorgan Chase & Co. (NYSE: JPM) ("JPMorgan Chase" or the "Firm") will host a conference call to review second-quarter 2024 financial results on Friday, July 12, 2024 at 8:30 a.m. (EDT). The results are scheduled to be released at approximately 7:00 a.m. (EDT). The live audio webcast and presentation slides will be available on www.jpmorganchase.com under Investor Relations, Events & Presentations.